Form 4: Protara Therapeutics Director Luke M. Beshar Acquires 10,000 Stock Options
SEC Form 4 Filing
Director Luke M. Beshar acquired 10,000 stock options in Protara Therapeutics, Inc. on June 7, 2024.
Summary
- On June 7, 2024, Luke M. Beshar, a director of Protara Therapeutics, Inc., acquired 10,000 stock options.
- The exercise price of these options is $2.67.
- The options vest in equal monthly installments over 12 months, with full vesting by the next annual stockholder meeting or upon a change of control, contingent on continuous service on the Board.
- The options expire on June 6, 2034.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing stock option grants. It doesn't inherently convey positive or negative sentiment.
Future Outlook
The stock options vest over the next 12 months, contingent on continued service as a board member, or will fully vest upon a change of control.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company directors.
Key Dates
| Date | Description |
|---|---|
| 06/07/2024 | Date of transaction: Luke M. Beshar acquired 10,000 stock options. |
| 06/06/2034 | Expiration date of the stock options. |
| 06/10/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.